Lorenzo Falchi

22PUBLICATIONS
174CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 31, 2026
Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.

|Aug 20, 2026
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial.

|Aug 05, 2026
First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

|Jul 08, 2026
Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

|Jun 30, 2026
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

|Jun 09, 2026
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Pageof 4

Frequent Collaborators

12 joint publications

Gilles Salles

7 joint publications

Maria Lia Palomba

7 joint publications

Andrew Zelenetz

6 joint publications

Ahmet Dogan